

- AS concluded.
- 5 cytolytic immune response or cytotoxic effect against a targeted cell, conjugated to a targeting domain comprising a mutant form of factor VII that binds to tissue factor and has reduced blood clotting activity.
- 

13. A method according to claim 9 which is a treatment for a disease selected from the group consisting of cancer involving a vascularized tumor, rheumatoid arthritis, the exudative form of macular degeneration, and atherosclerosis.

A 6  
14. A method according to claim 9 wherein the patient is treated by administration of an immunoconjugate protein in a pharmaceutically acceptable carrier.

15. A method according to claim 9 wherein the patient is treated by administration of a replication-deficient adenoviral vector or an adeno-associated vector carrying a cDNA encoding a secreted form of one or more types of immunoconjugate protein.

---

10030203-123104  
A 7  
19. A method according to claim 17 wherein the patient is treated by administering the immunoconjugate in a pharmaceutically acceptable carrier.

20. A method according to claim 17 wherein the patient is treated by administering a replication-deficient adenoviral vector carrying a cDNA encoding a secreted form of one or more types of the immunoconjugate protein.

---

Please add the following new claims 21 to 24:

---

A 8  
21. A composition according to claim 1 wherein the immunoconjugate protein is constructed as a dimer of two identical chains, each having an effector domain and a targeting domain.

22. A composition according to claim 1 wherein the effector domain is the Fc region of an IgG1 immunoglobulin.